Table 2.
Expression level of the fms-like tyrosine kinase 3 (FLT3) transcript and clinical characteristics in chronic myelogenous leukemia (CML) used by quantitative polymerase chain reaction*
| Characteristics | CML chronic phase (n = 10) | CML acceleration phase (n = 7) | CML blast crisis (n = 10) | P† |
|---|---|---|---|---|
| PBWBC count ( × 109/L, mean±SD) |
41.0 ± 7.5 |
80.6 ± 8.1 |
113.2 ± 46.4 |
0.001‡ |
| 0.089§ | ||||
| Percentage of blasts in the bone marrow |
0.030 ± 0.009 |
0.15 ± 0.03 |
0.642 ± 0.182 |
0.001‡ |
| 0.001§ | ||||
| Expression level of FLT3 mRNA (FLT3/GAPDH) |
0.002 |
0.004 |
0.017 |
0.307‡ |
| 0.023§ | ||||
| Surface expression of FLT3 receptor protein | 0.067 ± 0.019 | 0.10 ± 0.01 | 0.158 ± 0.030 | 0.002‡ |
| 0.001§ |
*Abbreviations: PBWBC – peripheral blood white blood cell; GAPDH – glyceraldehyde 3-phosphate dehydrogenase.
†Student Newman-Keuls test.
‡CML chronic phase in comparison with CML acceleration phase.
§CML acceleration phase in comparison with CML blast crisis.